Mesothelioma  >>  Tecentriq (atezolizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
AtezoMeso, NCT04996017 / 2020-003762-39: Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

Recruiting
3
162
Europe
Atezolizumab 1200 mg in 20 ML Injection, Placebo
Gruppo Oncologico Italiano di Ricerca Clinica, Roche S.p.A.
Mesotheliomas Pleural
12/23
12/23
BEAT-meso, NCT03762018 / 2018-002180-25: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Active, not recruiting
3
401
Europe
Carboplatin, Carboplatin Accord, Pemetrexed, Alimta, Bevacizumab, Avastin, Atezolizumab, Tecentriq, RO5541267
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Pleural Mesothelioma Malignant Advanced
06/24
06/24

Download Options